![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sfa-therapeutics-strengthens-management-team-with-appointment-of-chief-operating-officer-302194031.html
https://www.prnewswire.com/news-releases/sfa-therapeutics-announces-completion-of-enrollment-in-phase-1b-trial-of-sfa-002-for-psoriasis-302158420.html
https://www.prnewswire.com/news-releases/sfa-therapeutics-strengthens-management-team-with-appointment-of-chief-medical-officer-302132292.html
https://www.globenewswire.com//news-release/2023/11/09/2777360/0/en/SFA-Therapeutics-Announces-Updated-Psoriasis-Data-for-SFA-002-Bridge-Financing-and-Foundational-Patent.html
https://www.globenewswire.com/news-release/2023/08/14/2724489/0/en/SFA-Therapeutics-announces-results-for-SFA-002-from-Phase-1b-Cohort-1-clinical-trial-for-treatment-of-mild-to-moderate-psoriasis.html
https://www.prnewswire.com/news-releases/sfa-therapeutics-announces-fda-clearance-for-amendment-to-extend-phase-1b-trial-of-sfa-002-for-psoriasis-301717792.html
https://www.einnews.com/pr_news/595731479/dr-daniel-sauder-joins-the-sfa-therapeutics-scientific-advisory-board